HDX-MS study on garadacimab binding to activated FXII reveals potential binding interfaces through differential solvent exposure.

MLA

Ow, Saw Yen, et al. “HDX-MS Study on Garadacimab Binding to Activated FXII Reveals Potential Binding Interfaces through Differential Solvent Exposure.” MAbs, vol. 15, no. 1, Jan. 2023, p. 2163459. EBSCOhost, https://doi.org/10.1080/19420862.2022.2163459.

APA

Ow, S. Y., Kapp, E. A., Tomasetig, V., Zalewski, A., Simmonds, J., Panousis, C., Wilson, M. J., Nash, A. D., & Pelzing, M. (2023). HDX-MS study on garadacimab binding to activated FXII reveals potential binding interfaces through differential solvent exposure. MAbs, 15(1), 2163459. https://doi.org/10.1080/19420862.2022.2163459

Chicago

Ow, Saw Yen, Eugene A Kapp, Vesna Tomasetig, Anton Zalewski, Jason Simmonds, Con Panousis, Michael J Wilson, Andrew D Nash, and Matthias Pelzing. 2023. “HDX-MS Study on Garadacimab Binding to Activated FXII Reveals Potential Binding Interfaces through Differential Solvent Exposure.” MAbs 15 (1): 2163459. doi:10.1080/19420862.2022.2163459.